Vyome Biosciences today said Managing Director and CEO of Manipal Education & Medical Group Ranjan Pai has joined its Board of Directors.
Pai's venture capital firm Aarin Capital is an investor in Vyome. The has company also appointed Richard Buchta, formerly Head of GlaxoSmithKline's dermatology unit Stiefel Laboratories in Australia, as Senior Vice-President of R&D. "As Vyome scales operations and prepares to enter the commercialisation phase, his (Dr Ranjan Pai's) addition adds tremendous strategic experience to the Board," Vyome Co-founder & CEO N Venkat said in a statement.
The globalisation and expansion of the Manipal Education and Medical Group through his strategic vision is an experience that will serve Vyome in good stead as the company looks abroad for development and licensing opportunities, he added.
Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.